Lotfi Benboubker

Spinal manifestations of diffuse large B-cell lymphoma

Aymeric Amelot, Louis‐Marie Terrier, Gabrielle Cognacq, Lotfi Benboubker et autres

fr, gb (code pays fourni par la source)

P-074 Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma

Laura Rosiñol, Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall et autres

MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Niels WCJ van de Donk, Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall et autres

nl, us, fr, se, es, be (code pays fourni par la source)

Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf et autres

fr, nl, be (code pays fourni par la source)

Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)

Niels WCJ van de Donk, Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall et autres

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf et autres

fr, ca, nl, be, us, gb (code pays fourni par la source)

Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).

Niels W.C.J. van de Donk, Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall et autres

nl, us, fr, se, es (code pays fourni par la source)

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Arthur Bobin, Salomon Manier, Joe De Keizer, Cyrille Hulin et autres

fr, us, ch (code pays fourni par la source)

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Arthur Bobin, Jérôme Lambert, Stéfanie Ragot, Aurore Perrot et autres

fr, us (code pays fourni par la source)

MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Saad Z. Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi et autres

us, nl, fr, se, es (code pays fourni par la source)

POSTER: MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Saad Z. Usmani, Lionel Karlin, Lotfi Benboubker, Hareth Nahi et autres

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial

Paul G. Richardson, Thierry Façon, Christopher P. Venner, Nizar J. Bahlis et autres

us, fr, ca, be, kr, jp (code pays fourni par la source)